Indaptus Therapeutics, Inc.
INDP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001857044
No open-market purchases or sales by Indaptus Therapeutics, Inc. insiders were filed in the last 90 days; 9 institutions reported holding it in 13F filings for Q2 2026, worth $1.15M in total; no superinvestor holds it.
Q4 2024 vs. Q3 2024
How the institutions holding Indaptus Therapeutics, Inc. changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Q4 2024 | Change |
|---|---|---|---|
| Holders | 18 | 20 | +2 |
| Shares | 605.0K | 638.4K | +33.4K (+5.5%) |
| Value | $750.2K | $539.6K | −$210.7K (−28.1%) |
New holders (3)
Institutions that held Indaptus Therapeutics, Inc. at the end of Q4 2024 but not at the end of Q3 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Susquehanna International Group, LLP | 17,829 | $15.0K | 0.00% |
| Two Sigma Securities, LLC | 16,620 | $14.0K | 0.00% |
| SBI Securities Co., Ltd. | 3,900 | $3.28K | 0.00% |
Sold out (1)
Institutions that held Indaptus Therapeutics, Inc. at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Citadel Advisors LLC | 15,390 | $19.1K |